| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.sanjivani.co.in | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 24.86 Cr. | |
| Earnings per share (EPS) | 1.67 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 17.51 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 35.17 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | -52.83 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | -0.55 | Calculated using Price: 29.25 |
| Dividend Yield | 0.00 | Period Ending 2020-03 |
| No. of Shares Subscribed | 0.85 Cr. | 8,498,300 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Sanjivani Parenteral was established in 1997 by A H Khemka, Ashwin Khemka and Somesh Khemka, under the technical direction of Mahendra Kalwankar. It is a research-based, international pharmaceutical company that provides a wide range of high quality products and services at affordable prices. The core product range of the company’s products includes oral solids, small volume parenterals and sterile powder formulations. The company has grown many folds and aspires to be a respected research-based company. With its diverse product portfolio, it is rapidly expanding its reach to the global marketplace, riding on its success in India and in the world’s emerging and developed markets. After establishing itself in India, Sanjivani has extended its reach globally by entering the markets of Asia, Europe, Africa and Latin America. The company has active presence in countries like Russia, Ukraine, Uzbekistan, Turkmenistan, Fiji, Vietnam, Sri Lanka, Nepal, Malaysia, Thailand, Nigeria and Peru, to name a few. Sanjivani Parenteral has also got its plant approved by the registration authorities of Congo, Sudan and Sri Lanka. It is making its presence felt in the world market now, through leveraging its manufacturing capacity, quality of products and international alliances. International business contributes about 30% of the company’s revenue and is set to grow to more than 50% in the coming two years. This includes the sales of Sanjivani’s own brands and the revenue from the contract manufacturing services that the company provides to its overseas clients. The company is in the making of a strong base to broaden its horizons. Sanjivani has been a regular supplier to the armed forces’ hospitals in India. Furthermore, many government and private hospitals have availed of the products and services offered by Sanjivani across the country. The company also has its own marketing operations in India and boasts of over 1000 distributors all over India. Products
|
||
Company Profile
Sanjivani Parenteral was established in 1997 by A H Khemka, Ashwin Khemka and Somesh Khemka, under the technical direction of Mahendra Kalwankar. It is a research-based, international pharmaceutical company that provides a wide range of high quality products and services at affordable prices. The core product range of the company’s products includes oral solids, small volume parenterals and sterile powder formulations.
The company has grown many folds and aspires to be a respected research-based company. With its diverse product portfolio, it is rapidly expanding its reach to the global marketplace, riding on its success in India and in the world’s emerging and developed markets.
After establishing itself in India, Sanjivani has extended its reach globally by entering the markets of Asia, Europe, Africa and Latin America. The company has active presence in countries like Russia, Ukraine, Uzbekistan, Turkmenistan, Fiji, Vietnam, Sri Lanka, Nepal, Malaysia, Thailand, Nigeria and Peru, to name a few. Sanjivani Parenteral has also got its plant approved by the registration authorities of Congo, Sudan and Sri Lanka. It is making its presence felt in the world market now, through leveraging its manufacturing capacity, quality of products and international alliances.
International business contributes about 30% of the company’s revenue and is set to grow to more than 50% in the coming two years. This includes the sales of Sanjivani’s own brands and the revenue from the contract manufacturing services that the company provides to its overseas clients. The company is in the making of a strong base to broaden its horizons.
Sanjivani has been a regular supplier to the armed forces’ hospitals in India. Furthermore, many government and private hospitals have availed of the products and services offered by Sanjivani across the country. The company also has its own marketing operations in India and boasts of over 1000 distributors all over India.
Products
| 1 Day |
|
+4.84% |
| 1 Week |
|
+21.12% |
| 1 Month |
|
+125.87% |
| 3 Month |
|
+165.91% |
| 6 Month |
|
+184.53% |
| 1 Year |
|
+228.65% |
| 2 Year |
|
+257.14% |
| 5 Year |
|
+35.42% |
| 9 years | 2012-03 | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | 9.06 | 7.55 | 4.66 | -7.19 | -58.98 | -596.93 | ||||
| Return on Capital Employed (%) | 14.57 | 13.03 | 12.18 | 5.69 | -7.28 | -33.04 | -227.28 | -265.98 | ||
| Return on Assets (%) | 2.56 | 2.19 | 1.38 | -2.09 | -14.16 | -34.18 | -124.34 | -9.62 | -10.16 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 31 | 33 | 35 | 32 | 18 | -9 | -53 | -47 | -49 | |
| Non Curr. Liab. | 12 | 9 | 8 | 7 | 14 | 9 | 6 | 10 | 9 | |
| Curr. Liab. | 66 | 71 | 74 | 75 | 62 | 61 | 72 | 56 | 55 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 109 | 113 | 117 | 114 | 93 | 60 | 25 | 18 | 16 | |
| Non Curr. Assets | 26 | 26 | 27 | 16 | 23 | 17 | 16 | 11 | 12 | |
| Curr. Assets | 84 | 87 | 90 | 98 | 70 | 43 | 9 | 7 | 4 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 109 | 113 | 117 | 114 | 93 | 60 | 25 | 18 | 16 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 150 | 152 | 159 | 133 | 115 | 33 | 18 | 25 | 16 | |
| Other Income | 2 | 2 | 3 | 1 | 1 | 3 | 0 | 1 | 0 | |
| Total Income | 152 | 154 | 161 | 135 | 116 | 36 | 18 | 26 | 17 | |
| Total Expenditure | -139 | -141 | -149 | -128 | -121 | -56 | -70 | -27 | -17 | |
| PBIDT | 13 | 13 | 12 | 7 | -5 | -20 | -52 | -1 | 0 | |
| Interest | -9 | -8 | -8 | -8 | -9 | -5 | 0 | 0 | -1 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | -1 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Exceptional Items | 0 | |||||||||
| PAT | 3 | 2 | 2 | -2 | -15 | -26 | -53 | -2 | -2 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 9 | 7 | 9 | -1 | 0 | 10 | 3 | 2 | 0 | |
| Cash Fr. Inv. | -8 | -1 | -1 | 9 | -1 | 0 | 0 | 0 | 0 | |
| Cash Fr. Finan. | -1 | -6 | -8 | -7 | -1 | -10 | -3 | -2 | 0 | |
| Net Change | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | |
| Cash & Cash Eqvt | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
|
Sat, 17 Jul 2021
Board Meeting Intimation for Approval The Un-Audited Financial Results Of The Company For The Quarter And Financial Year Ended June 30 2021. SANJIVANI PARANTERAL LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2021 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of Sanjivani Paranteral Limited will be held on Tuesday 26th July 2021 inter alia 1. To consider and approve the Un-Audited Financial Results of the Company for the quarter and financial year ended June 30 2021. 2. Any other matter with the permission of the chair. Kindly take note of the above on record. |
||||||||||||||
|
Fri, 09 Jul 2021
Quarterly Disclosures By Listed Entities Of Defaults On Payment Of Interest/ Repayment Of Principal Amount On Loans From Banks / Financial Institutions And Unlisted Debt Securities Quarterly Disclosures by listed entities of defaults on payment of interest/ repayment of principal amount on loans from banks / financial institutions and unlisted debt securities |
||||||||||||||
|
Fri, 09 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
|
| Fri, 23 Jul 2021 |
Stock Outperforming Benchmark Index in both 1 Week and 3 Month
|
Stock Outperforming Sectoral Index in both 1 Week and 3 Month
|
Strongly Outperforming Benchmark Index
|
Strongly Outperforming Sectoral Index
|
Increasing Relative Strength - Sectoral Index
|
Equities
M.F.
Sectors